Sanofi (SNY) Earnings History
Annual and quarterly earnings data from 1999 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 72.3% | 13.6% | 16.7% |
| 2024 | 70.2% | 16.4% | 12.6% |
| 2023 | 69.7% | 16.7% | 13.0% |
| 2022 | 70.7% | 25.1% | 20.6% |
| 2021 | 68.7% | 20.7% | 15.9% |
Download Data
Export SNY earnings history in CSV or JSON format
Free sign-in required to download data
Sanofi (SNY) Earnings Overview
As of March 2, 2026, Sanofi (SNY) reported trailing twelve-month net income of $7.81B, reflecting -0.1% year-over-year growth. The company earned $3.20 per diluted share over the past four quarters, with a net profit margin of 0.2%.
Looking at the long-term picture, SNY's 5-year EPS compound annual growth rate (CAGR) stands at -16.2%, signaling declining earnings. The company achieved its highest annual net income of $12.29B in fiscal 2020.
Sanofi maintains positive profitability with a gross margin of 0.7%, operating margin of 0.1%, and net margin of 0.2%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including MRK ($18.25B net income, 0.3% margin), PFE ($7.77B net income, 0.1% margin), GSK ($5.71B net income, 0.2% margin), SNY has room to improve margins relative to the peer group. Compare SNY vs MRK →
Peer Comparison
Earnings metrics vs industry competitors
| Company | TTM Net Income | TTM EPS | Net Margin | ROE | YoY Growth | Compare |
|---|---|---|---|---|---|---|
SNYCurrent | $7.8B | $3.20 | 0.2% | 0.1% | -0.1% | — |
MRK | $18.3B | $7.34 | 0.3% | 0.4% | +0.1% | |
PFE | $7.8B | $1.37 | 0.1% | 0.1% | -0.0% | |
GSK | $5.7B | $2.79 | 0.2% | 0.4% | +1.2% | |
GRFS | $373M | $0.55 | 0.0% | 0.0% | +1.6% |
Historical Data
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.81B | +40.5% | $6.34B | $2.03 | 16.7% | 13.6% |
| 2024 | $5.56B | +3.0% | $7.25B | $2.19 | 12.6% | 16.4% |
| 2023 | $5.40B | -35.5% | $6.96B | $2.15 | 13.0% | 16.7% |
| 2022 | $8.37B | +34.5% | $10.16B | $3.18 | 20.6% | 25.1% |
| 2021 | $6.22B | -49.4% | $8.13B | $2.49 | 15.9% | 20.7% |
| 2020 | $12.29B | +346.4% | $14.11B | $4.91 | 32.9% | 37.8% |
| 2019 | $2.75B | -36.0% | $3.05B | $1.14 | 7.3% | 8.1% |
| 2018 | $4.31B | -48.8% | $4.68B | $1.73 | 12.1% | 13.1% |
| 2017 | $8.42B | +78.7% | $5.80B | $3.36 | 23.2% | 16.0% |
| 2016 | $4.71B | +9.8% | $6.53B | $1.83 | 13.6% | 18.8% |
See SNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNY Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SNY vs AGIO
See how SNY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SNY growing earnings?
SNY EPS of $3.20 reflects slowing growth at -0.1%, below the 5-year CAGR of -16.2%. TTM net income is $7.8B. Expansion rate has moderated.
What are SNY's profit margins?
Sanofi net margin is +0.2%, with operating margin at +0.1%. Below-average margins reflect competitive or cost pressures.
How consistent are SNY's earnings?
SNY earnings data spans 1999-2025. The current earnings trend is -0.1% YoY. Historical data enables comparison across business cycles.